The protective effect of montelukast sodium on carbon tetrachloride induced hepatopathy in rat.
OBJECTIVE
This study investigates the effects of montelukast sodium (MK) (CysLTLT1 receptor antagonist) on CCl(4)induced hepatopathy on rat.


METHODS
We worked on 4 groups of 10 Wistar male rats each. The groups received as follows: group I (control group) - saline, group II - MK 5mg/kg/day i.p. for 5 days, group III - MK 5mg/kg/day i.p., 1 day prior to and 4 days concomitantly with CCl(4) p.o., 0.3ml/Kg/day and group IV - CCl(4), p.o., 0.3ml/Kg/day for 4 days. One day after the last administration, samples of blood were taken and alanine aminotransferase (ALT), total bilirubin (TB), direct bilirubin (DB), malondialdehyde (MDA), catalase (CAT) as well as total antioxidant capacity (TAC) were determined. The histopathological exam was performed. We also determined superoxide dismutase (SOD), MDA, CAT and GSH in liver homogenate.


RESULTS
Compared to group IV, group III exhibited statistically significant lower levels of ALT (318+/-15.75 versus 203.14+/-10.28 UI, p<0.0001), TB (3.16+/-0.30 versus 1.99+/-0.08mg/dl, p<0.0001), MDA in blood and in liver homogenate (4.98+/-1.71 versus 2.15+/-1.18nmol/ml, p=0.0004) and higher levels of SOD and CAT. Histopathologically, group IV presented important macro- and micro-vesicular hepatic steatosis and group III preserved lobular histoarchitecture and had less severe cellular lesions.


CONCLUSIONS
MK exhibits a partial hepatoprotective effect on rats treated with CCl(4).
Cuciureanu
Magdalena
M
Department of Pharmacology, University of Medicine and Pharmacy, GRIGORE T. POPA, IASI, Romania. magdacuciur@gmail.com
Căruntu
Irina-Draga
ID
Păduraru
Ofelia
O
Stoica
Bogdan
B
Jerca
Luminita
L
Crauciuc
Eduard
E
Nechifor
Mihai
M
D000085:Acetates / Q000494:pharmacology*; D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D001663:Bilirubin / Q000378:metabolism; D002251:Carbon Tetrachloride / Q000633:toxicity*; D002374:Catalase / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D003521:Cyclopropanes; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides; D013482:Superoxide Dismutase / Q000378:metabolism
D000085:Acetates; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D008315:Malondialdehyde; D002251:Carbon Tetrachloride; D002374:Catalase; D013482:Superoxide Dismutase; D000410:Alanine Transaminase; C093875:montelukast; D001663:Bilirubin